Telomir Pharmaceuticals (TELO) Competitors $1.33 -0.03 (-2.21%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.29 -0.04 (-2.71%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TELO vs. ALTS, BTMD, CTOR, SXTC, NVCT, MCRB, LFVN, KYTX, MEIP, and BDTXShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include ALT5 Sigma (ALTS), biote (BTMD), Citius Oncology (CTOR), China SXT Pharmaceuticals (SXTC), Nuvectis Pharma (NVCT), Seres Therapeutics (MCRB), Lifevantage (LFVN), Kyverna Therapeutics (KYTX), MEI Pharma (MEIP), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. Its Competitors ALT5 Sigma biote Citius Oncology China SXT Pharmaceuticals Nuvectis Pharma Seres Therapeutics Lifevantage Kyverna Therapeutics MEI Pharma Black Diamond Therapeutics Telomir Pharmaceuticals (NASDAQ:TELO) and ALT5 Sigma (NASDAQ:ALTS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment. Do analysts recommend TELO or ALTS? Telomir Pharmaceuticals currently has a consensus price target of $15.00, indicating a potential upside of 1,027.82%. Given Telomir Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Telomir Pharmaceuticals is more favorable than ALT5 Sigma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50ALT5 Sigma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of TELO or ALTS? 6.3% of ALT5 Sigma shares are held by institutional investors. 4.9% of ALT5 Sigma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer TELO or ALTS? In the previous week, ALT5 Sigma had 3 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 8 mentions for ALT5 Sigma and 5 mentions for Telomir Pharmaceuticals. ALT5 Sigma's average media sentiment score of 0.30 beat Telomir Pharmaceuticals' score of -0.43 indicating that ALT5 Sigma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telomir Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral ALT5 Sigma 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is TELO or ALTS more profitable? Telomir Pharmaceuticals has a net margin of 0.00% compared to ALT5 Sigma's net margin of -74.89%. ALT5 Sigma's return on equity of -179.27% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Telomir PharmaceuticalsN/A -4,595.08% -1,750.91% ALT5 Sigma -74.89%-179.27%-16.28% Which has better earnings & valuation, TELO or ALTS? ALT5 Sigma has higher revenue and earnings than Telomir Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelomir PharmaceuticalsN/AN/A-$16.53M-$0.54-2.46ALT5 Sigma$12.53M6.76-$6.24MN/AN/A Which has more volatility & risk, TELO or ALTS? Telomir Pharmaceuticals has a beta of -0.72, suggesting that its share price is 172% less volatile than the S&P 500. Comparatively, ALT5 Sigma has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500. SummaryALT5 Sigma beats Telomir Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.90M$2.56B$5.80B$10.17BDividend YieldN/A57.22%5.72%4.61%P/E Ratio-2.4623.4975.0526.39Price / SalesN/A684.43544.00190.24Price / CashN/A27.5625.8129.91Price / Book66.505.4013.436.28Net Income-$16.53M$32.95M$3.29B$270.38M7 Day Performance-2.21%-0.53%0.08%1.89%1 Month Performance-10.74%4.23%4.61%6.01%1 Year Performance-77.80%-2.81%75.02%25.26% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir Pharmaceuticals1.9825 of 5 stars$1.33-2.2%$15.00+1,027.8%-78.1%$43.90MN/A-2.461ALTSALT5 Sigma0.1879 of 5 stars$5.58-29.2%N/A+79.8%$170.28M$12.53M0.00170High Trading VolumeBTMDbiote2.867 of 5 stars$3.43-0.3%$6.00+74.9%-41.1%$170.07M$197.19M3.81194News CoveragePositive NewsCTORCitius Oncology1.8 of 5 stars$2.01-7.4%$3.00+49.3%+12.9%$170.06MN/A0.00N/ASXTCChina SXT Pharmaceuticals1.292 of 5 stars$1.42-2.7%N/A-65.1%$169.40M$1.74M0.0090News CoveragePositive NewsShort Interest ↓Gap DownNVCTNuvectis Pharma3.4718 of 5 stars$6.38-2.7%$15.33+140.3%-7.2%$167MN/A-5.458MCRBSeres Therapeutics3.0849 of 5 stars$19.52+3.1%$73.67+277.4%-21.5%$165.81M$126.32M-4.24330Positive NewsGap UpLFVNLifevantage4.0095 of 5 stars$13.55+3.4%$30.50+125.1%+1.7%$164.90M$200.16M19.64260Positive NewsHigh Trading VolumeKYTXKyverna Therapeutics2.7765 of 5 stars$3.59-3.2%$16.60+362.4%-45.7%$160.44M$7.03M-0.9896Gap UpMEIPMEI Pharma1.4862 of 5 stars$4.85-0.2%N/A+5.2%$159.59MN/A-1.02100Upcoming EarningsGap UpBDTXBlack Diamond Therapeutics3.5564 of 5 stars$2.80+1.8%$12.40+342.9%-48.5%$156.57MN/A12.1790Positive News Related Companies and Tools Related Companies ALT5 Sigma Alternatives biote Alternatives Citius Oncology Alternatives China SXT Pharmaceuticals Alternatives Nuvectis Pharma Alternatives Seres Therapeutics Alternatives Lifevantage Alternatives Kyverna Therapeutics Alternatives MEI Pharma Alternatives Black Diamond Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TELO) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TELO Stock Alerts